Capital Wealth Planning LLC Raises Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Capital Wealth Planning LLC grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 161,350 shares of the company’s stock after purchasing an additional 7,620 shares during the period. Capital Wealth Planning LLC’s holdings in Teva Pharmaceutical Industries were worth $2,622,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in TEVA. Maple Rock Capital Partners Inc. boosted its position in shares of Teva Pharmaceutical Industries by 68.3% in the 1st quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock worth $61,568,000 after buying an additional 1,770,000 shares in the last quarter. Glenview Capital Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $16,752,000. Iron Triangle Partners LP raised its stake in Teva Pharmaceutical Industries by 113.1% in the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock valued at $39,083,000 after purchasing an additional 1,469,864 shares during the last quarter. Norges Bank acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at about $14,376,000. Finally, Hsbc Holdings PLC raised its stake in Teva Pharmaceutical Industries by 242.6% in the 4th quarter. Hsbc Holdings PLC now owns 1,597,178 shares of the company’s stock valued at $16,667,000 after purchasing an additional 1,130,969 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Up 2.2 %

NYSE TEVA opened at $18.41 on Monday. The stock has a market cap of $20.86 billion, a PE ratio of -44.90, a P/E/G ratio of 1.26 and a beta of 0.88. Teva Pharmaceutical Industries Limited has a fifty-two week low of $8.06 and a fifty-two week high of $19.08. The business has a 50 day moving average price of $17.55 and a two-hundred day moving average price of $15.95. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The firm had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several analyst reports. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday, July 10th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 3rd. Jefferies Financial Group upped their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Finally, Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $18.89.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares in the company, valued at approximately $777,285. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Eric A. Hughes sold 24,537 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Roberto Mignone sold 519,000 shares of the stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the transaction, the director now owns 981,000 shares of the company’s stock, valued at $16,706,430. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.